People who get GLP-1s are different than those who dont
And this is what I tell my patients every time we come to a point of deciding if they should start a new medication and what should that medication be
Impure products can contain harmful contaminants, be underdosed, or have incorrect peptide sequences, which will invalidate research results and pose significant safety risks
Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received RYBELSUS than placebo: RYBELSUS 14 mg once daily (41%), RYBELSUS 7 mg once daily (32%) and placebo (21%), including severe reactions (RYBELSUS 14 mg 2.0%, RYBELSUS 7 mg 0.6%, placebo 0.3%)
However, the effectiveness of each depends on the specific needs of the patient